Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: A placebo-controlled evaluation in healthy subjects

Journal of Alternative and Complementary Medicine

Volumn 8, Issue 6, 2002, Pages 857-866

  Huber, Roman ^a   Klein, Reinhild ^b   Berg, Peter A ^b   Lüdtke, Rainer ^c   Werner, Michael ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Karl and Veronica Carstens Foundation   (Germany)

^d Institut Hiscia   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HAPTOGLOBIN; ISCADOR PINI; ISCADOR QU SPECIAL; LECTIN; PLANT TOXIN; UNCLASSIFIED DRUG; VISCOTOXIN; VISCUM ALBUM EXTRACT;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ECZEMA; EOSINOPHILIA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HEMATOLOGY; HERBAL MEDICINE; HUMAN; IMMUNOMODULATION; LEUKOCYTE DIFFERENTIAL COUNT; LIVER TOXICITY; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TASTE DISORDER; VERTIGO; VISCUM ALBUM;

EID: 0036979452     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/10755530260511847     Document Type: Article

References (25)

1. Ader R, Cohen N, Felten D. Psychoneuroimmunology: Interactions between the nervous system and the immune system. Lancet 1995;345:99-103.
2. Beuth J, Gabius HJ, Steuer MK, Geisel J, Steuer M, Ko HL, Pulverer G. Influence of mistletoelectin treatment on serum levels of defined serum proteins (acute phase proteins) in tumor patients). Med Klin 1993;88:287-290.
3. Drug Commission of the German Physicians Society. Comments to reports about adverse drug effects after treatment with mistletoe extracts and organo-/enzyme preparations in tumour disease. Dt Ärztebl 1997;94/17:922-923.
4. Fischer S, Scheffler A, Kabelitz D. Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol 1997;44:150-158.
5. Franz H. Mistletoe lectins and their A and B chains. Oncology 1986;43(suppl):23-34.
6. Friess H, Berger HG, Kunz J, Funk N, Schilling M, Büchler MW. Treatment of advanced pancreatic cancer with mistletoe: Results of a pilot trial. Anticancer Res 1996;16:915-920.
7. Hajto T, Hostanska K, Gabius HJ. Modulatory potencies of the beta-galactoside-specific lectin from mistletoe extracts (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989;49:4803-4808.
8. Hajto T, Hostanka K, Frei K, Rordorf C, Gabius HJ. Increased secretion of TNFα, IL-1 and IL-6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 1990;50:3322-3326.
9. Hajto T, Hostanska K, Fischer J, Lentzen H. Investigation of cellular parameters to establish the response of a biomodulator: Galactoside-specific lectin from Viscum album plant extract. Phytomedicine 1996;3:129-137.
10. Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 1994;14:1339-1342.
11. Heiny BM, Albrecht V, Beuth J. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 1998;18:583-586.
12. Huber R, Barth H, Schmitt-Gräff A, Klein R. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Alternative Complement Med 2000;6:305-310.
13. Institut Hiscia and Weleda AG, eds. Iscador. Iscador Information for Health Professionals. Switzerland: Verein für Krebsforschung Arlesheim, 1996.
14. Kleijnen J, Knipschild P. Mistletoe treatment for cancer: Review of controlled trials in humans. Phytomedicine 1994;14:255-260.
15. Klein R, Claßen K, Berg PA, Luedtke R, Werner M, Huber R. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: A randomised double-blinded placebo controlled phase I study in healthy individuals. Eur J Med Res 2002;7:155-163.
16. Pichler WJ, Angeli R. [Allergic reaction to mistletoe extract]. Dtsch Med Wochenschr 1991;116:1333-1334.
17. Penter R. Clinical observations with high temperature therapy under a high dosage of mistletoe preparations in cancer treatment. In: Scheer R, Becker H, Berg PA, Fintelmann V, eds. Die Mistel in der Tumortherapie. Essen: KVC-Verlag, 2001:423-444.
18. Schultze JL, Stettin A, Berg PA. Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract. Klin Wochenschr 1991;69:397-403.
19. Stein GM, Meink H, Durst J, Berg PA. Release of cytokines by a fermented lectin-1 (ML-1) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumour patients. Eur J Clin Pharmacol 1996;151:247-252.
20. Stein GM, Henn W, V.Laue HB, Berg PA. Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res 1998;3:194-202.
21. Stein GM, Schaller G, Pfüller U, Schietzel M, Büssing A. Thionins from Viscum album L: Influence of the viscotoxins on the activation of granulocytes. Anticancer Res 1999;19:1037-1042.
22. Stettin A, Schultze JL, Stechemesser E, Berg PA. Antimistletoe antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from viscum album 1. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr 1990;68:896-900.
23. Van Wely M, Stoss M, Gorter RW. Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. Am J Ther 1999;6:37-43.
24. Weihrauch TR. Placebo effects and adverse effects in clinical trials. Med Klin 2000;95(suppl):23-30.
25. Weis J, Bartsch HH, Hennies F, Rietschel M, Heim M, Adam G, Gärtner U, Ammon A. Complementary medicine in cancer patients: Demands, patients attitudes and psychological believes. Oncology 1998;21:144-149.